Close your eyes, breathe in deeply, now exhale slowly… That was easy, wasn’t it? Not for everyone…
Japan’s largest pharmaceutical company, Takeda, recently signed an agreement with Teva Pharmaceutical Industries to commercialize the Israeli company’s innovative treatment for Parkinson’s disease, rasagiline, in Japan.
The rasagiline tablets, which are approved in over 40 countries for the treatment of Parkinson’s disease, gained UK and EU-marketing authorization in 2005 and US FDA approval in 2006.
“It is estimated there are about 150,000-180,000 people diagnosed with Parkinson’s disease in Japan, many of whom are waiting for a new treatment option,” said Nancy Joseph-Ridge, M.D., General Manager of Takeda’s Pharmaceutical Development Division located in Osaka, Japan in a press release on April 27.
“We will continue working on the development in cooperation with Teva so that we can bring this medicine to Japanese patients as quickly as possible,” Joseph-Ridge said.
“This agreement represents Teva’s continued commitment to introducing our innovative medicines to patients in Japan,” added Teva Global R&D president and Chief Scientific Officer, Dr. Michael Hayden.
Teva and Takeda entered an agreement in December 2013 to develop glatiramer acetate for the treatment of multiple sclerosis.
Developed by Teva, rasagiline was initially discovered by two Haifa Technion professors, John Finberg and Moussa Youdim, who were instrumental in the early clinical development of the anti-Parkinson drug.
Parkinson’s disease is a degenerative disorder of the central nervous system, whose symptoms include shaking, rigidity, slowness of movement and difficultly with walking as well as dementia in advanced stages. An estimated seven to 10 million people suffer from the disease across the world according to the Parkinson’s Disease Foundation.
According to Teva’s website, rasagiline is a monoaxmine oxidase B (MAO-B) inhibitor that increases available synaptic dopamine in the brain, which might improve the motor symptoms characteristic of Parkinson’s, slowing the progression of the disease.
“Rasagiline has an established safety and efficacy profile…[it] will be an important product for Japan, where the number of available treatment options for Parkinson’s disease remains limited,” said Dr. Hayden.
About the Author: Anav Silverman is a regular contributor to Tazpit News Agency.
If you don't see your comment after publishing it, refresh the page.
Comments are closed.
Brooklyn politicians and community leaders called on Cong. members to vote down the Nuclear Iran deal.
Both Carson and Trump are solidly behind Israel, but their real drawing card is that they are not politicians.
Oregon’s Jeff Merkley announced he is backing the nuclear deal, leaving Obama only three shy of a veto-proof majority.
Israel’s Elbit Systems has racked up two more sales, this time by its cyber security subsidiary Cyberbit to a European police force and an African enforcement agency. Elbit, listed on NASDAQ, did not disclose the amount of the sales. It set up the Cyberbit subsidiary earlier this year to include the cyber and intelligence divisions […]
The regime’s Fars [Read “Farce”] News Agency reported that three Israelis and Jordanians were killed.
Jaffa port is a nice little port with a pleasant promenade to walk around on.
Barenboim rejected from Iran because he’s a “Zionist”. The irony is overwhelming.
Debbie Wasserman Schultz, DNC chair, allegedly blocked a DNC resolution supporting the Iran Deal.
Dr. Sacks was one of the greatest, if not the greatest, neurologists.
Arab readers of the Arabic version of Aljazeera responded with astonishment at the restraint shown by an armed Israeli soldier, who was filmed while a group of female villagers physically assaulted him during a rally.
Palestinian Arab terrorists shot and wounded an Israeli driver on the road near Kedumim.
Firefighters in Galilee were able to stop a brush fire on Sunday from spreading into a wildfire.
An Israeli woman has allegedly flown to Turkey to cross the border into Syria to join ISIS.
PM Netanyahu told Italian PM Renzi during weekend talks in Florence Israel does not object to a “civilian” nuclear program in Iran.
Not satire: Hamas released a warning to its members to be cautious of further encounters with dolphins.
On board were 32 families including 95 children and 53 singles, of whom 12 will be joining the Israel Defense Forces.
The Temple Institute is working together with an Israeli cattleman to raise a red heifer in Israel.
The Israeli wetlands are among the 2,208 Ramsar wetland sites from across 169 countries around the world.
“The idea of adapting the unit actually came from our soldiers who recognized the need for it in the field,” explained Captain Dr. Lev.
The House of Bishops, led by Presiding Bishop Katharine Jefferts Schori, overwhelmingly defeated the Boycott, Divestment, Sanctions resolution.
Printed from: http://www.jewishpress.com/news/breaking-news/tevas-parkinson-drug-now-marketed-in-japan/2014/05/29/
Scan this QR code to visit this page online: